This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include our belief that subjects in the Phase 2 clinical trial of peramivir received adequate dosing by intramuscular injection for which HHS or the Food & Drug Administration (FDA) may not agree, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials or our peramivir program in general may not be successful, that the pivotal trial with Forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of Forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the requi
|SOURCE BioCryst Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved